The Placebo Arm Problem: Reading Hair Trials Without Getting Fooled

In hair loss trials, the placebo arm almost always shows net hair loss over time. Treatment efficacy is the difference between the treatment arm's outcome and placebo — not the absolute change from baseline.

Hair loss clinical trials have several methodological features that make naive reading misleading. The most important: the placebo arm is not a stable baseline — it is an active condition. AGA progresses without treatment, and placebo arm participants in well-designed trials show that progression clearly over time.

What the placebo arm shows

In the pivotal 2-year finasteride AGA trials, placebo arm participants lost approximately 15–25 hairs per cm² on phototrichogram in the 1 cm² vertex reference area. This is the untreated AGA trajectory quantified. The finasteride arm gained approximately 10–18 hairs per cm² over the same period. The clinically meaningful number is the treatment-placebo difference: approximately 25–40 hairs per cm² between treated and untreated patients after two years.

Presenting only the treatment arm's absolute gain (“finasteride grew +18 hairs per cm²”) without context looks less impressive than the full comparison (“treated men had approximately 35 more hairs per cm² than untreated after two years”). Both are accurate; only the comparison provides the clinical picture.

Trial duration and interpretability

AGA progresses slowly — the average annual vertex hair loss without treatment is perhaps 10–15% of follicle density over years. Short trials (6–12 months) may not show statistically distinguishable placebo arm hair loss because the within-person variance in phototrichogram counts is substantial relative to a single year's progression. Two-year and five-year trials produce far more interpretable placebo arms.

Endpoint heterogeneity across trials

Phototrichogram hair count is the most objective and reproducible endpoint. Subjective physician or patient assessment of “improved” vs “stable” vs “worse” is far more susceptible to placebo effect and observer bias. Hair weight (comparing cut hair mass in the reference zone) is used in some trials. Understanding which endpoint a particular trial used is essential for comparison across studies.

The evidence hierarchy for AGA trial endpoints: phototrichogram hair count > hair weight > global photographic assessment > physician subjective assessment > patient self-assessment. Conclusions drawn from lower-quality endpoints require more caution.